Literature DB >> 3952459

Adult acute non-lymphoblastic leukaemia: reliability and prognostic significance of pretreatment bone marrow S-phase size determined by flow cytofluorometry.

A Riccardi, M Danova, C Montecucco, G Ucci, E Cassano, M Giordano, G Mazzini, P Giordano.   

Abstract

46 adult patients with non-lymphoblastic acute leukaemia (AnLL) had pretreatment proliferative activity of bone marrow (BM) blasts determined simultaneously with propidium iodide DNA flow cytofluorometry (as the percentage of cells with DNA content intermediate between the diploid and the tetraploid values, 2n-4n cell %) and in vitro tritiated thymidine cytoautoradiography (as the labelling index, LI). They were then treated with the same chemotherapy regimen, including 2-3 courses of sequential vincristine, arabinosylcytosine and adriamycin, for response induction, and monthly courses of different cytostatics for maintenance. Median 2n-4n cell % was 9.9 and median LI was 5.9. A close linear relationship (r = 0.913, p less than 0.001) between the two parameters was found. Patients having a 2n-4n cell % greater than 15.6 responded more often to chemotherapy than patients having a lower percentage (p less than 0.05) but also experienced a shorter duration of first response (p less than 0.05). Overall survival was longer in patients with 2n-4n cell % greater than 15.6 (p less than 0.02). Multiple regression analysis indicates that 2n-4n cell % is a statistically significant (p less than 0.05) independent factor correlating with duration of response in adult AnLL.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3952459     DOI: 10.1111/j.1600-0609.1986.tb02643.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  5 in total

Review 1.  The myelodysplastic syndrome.

Authors:  D A Galton
Journal:  BMJ       Date:  1989-09-02

2.  Assessment of DNA content and cell cycle distribution of erythroid and myeloid cells from bone marrow.

Authors:  J Hodgetts; T G Hoy; A Jacobs
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

3.  Assessment of proliferative activity in leukaemic bone marrow using the monoclonal antibody Ki-67.

Authors:  D M White; A G Smith; J L Smith
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

4.  Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with granulocyte-macrophage colony-stimulating factor.

Authors:  A Riccardi; M Danova; A Paccagnella; M Giordano; A Favaretto; M Panozzo; C Ghiotto; S Comis; M Fiorentino; L Chieco-Bianchi
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

Review 5.  The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies.

Authors:  Stefan G C Mestrum; Anton H N Hopman; Frans C S Ramaekers; Math P G Leers
Journal:  Blood Adv       Date:  2021-04-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.